Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a lung cancer drug designed for one mutation work for another?

NCT ID NCT03445000

Terminated Disease control Sponsor: ETOP IBCSG Partners Foundation Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This phase II trial tests whether alectinib, a drug typically used for ALK-positive lung cancer, can shrink tumors or control disease in people with advanced non-small cell lung cancer that has a RET gene rearrangement and has progressed after prior treatment. Participants take alectinib capsules twice daily at home. The study measures how many patients have their tumors shrink or stabilize, with a focus on the best overall response and disease control at 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a drug called alectinib (Alecensa), taken orally as capsules twice daily
What this could lead to
If successful, this could provide a new treatment option for people with a specific genetic subtype of advanced lung cancer who have already tried other therapies.
What could go wrong
This is a small, early-phase trial with only 14 participants, so results may not apply broadly. The drug may not shrink tumors or control the disease as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER METASTATIC NON-SMALL CELL LUNG CANCER RECURRENT

Contacts and locations

Locations

  • HFR Fribourg

    Fribourg, Switzerland

  • Hospital Puerta de Hierro

    Madrid, Spain

  • Hospital Quirón Dexeus

    Barcelona, Spain

  • Hospital Regional Universitario Carlos Haya

    Málaga, Spain

  • Hospital Sant Pau

    Barcelona, Spain

  • Hospital Teresa Herrara

    A Coruña, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hospital general de Alicante

    Alicante, Spain

  • Hôpital Universitaire de Genève

    Geneva, Switzerland

  • IRCCS Instituto Tumori Giovanni Paolo II

    Bari, Italy

  • Institut Jules Bordet

    Brussels, Belgium

  • Instituto Europeo di Oncologia (IEO)

    Milan, Italy

  • St. James Hospital

    Dublin, Ireland

  • The Netherlands Cancer Institute Amsterdam

    Amsterdam, Netherlands

  • Universita di Verona

    Verona, Italy

  • UniversitatSpital Zurich

    Zurich, Switzerland

  • University Hospital of Turin

    Turin, Italy

  • University Medical Center Maastricht

    Maastricht, Netherlands

  • Vall d'Hebron University Hospital

    Barcelona, 08035, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.